| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 18, 2025 | Nabsys and Hitachi Present Electronic Genome Mapping Data at Japanese Society of Human Genetics (JSHG) 2025 Annual Meeting | TOKYO, Dec. 18, 2025 /PRNewswire/ -- Nabsys 2.0, LLC (Nabsys), a pioneer in electronic genome mapping technology, in partnership with Hitachi High-Tech Corporation (HHT) announces the presentation of high resolution structural variation dat... |
| Oct 23, 2025 | Danforth Health Acquires Asymmetry Group, Expanding Integrated Support for Life Science Commercialization | , announced the acquisition of Asymmetry Group, LLC, strengthening its ability to help scientific innovation reach market and achieve impact for patients.
The acquisition brings 30 seasoned experts in the areas of corporate advisory and com... |
| Jun 23, 2025 | OnCusp Therapeutics Appoints Dimitry Nuyten, M.D., Ph.D., as Chief Medical Officer | PRINCETON, N.J., June 23, 2025 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, tod... |
| Jun 2, 2025 | OnCusp Therapeutics Announces Encouraging Initial Phase 1a Results from Ongoing First-in-Human Study Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors at the 2025 ASCO Annual Meeting | CUSP06 is a CDH6-directed ADC with a differentiated profile and potentially best-in-class activity
CUSP06 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor ADCs
Promising signs of efficacy were observed in patie... |
| Apr 29, 2025 | Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update | Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024)
~25,000 prescriptions filled in Q1 2025
Q1 2025 revenue exceeds operating expenses excluding non-cash charges
Conference call ... |
| Apr 24, 2025 | Safi Biotherapeutics Awarded NIH STTR Grant to Improve Blood Transfusion Safety | Safi to bulk manufacture Children’s Hospital of Philadelphia’s iPSC-derived RBCs with rare antigen profiles as diagnostic tools for alloimmunized patients
We are pleased to partner with Dr. Chou on this proof-of-principle to scale the manuf... |
| Apr 15, 2025 | Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, Apri... |
| Feb 27, 2025 | Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024
More prescriptions filled through February 2025 than in Q4 2024
Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuva... |
| Feb 27, 2025 | Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024
More prescriptions filled through February 2025 than in Q4 2024
Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuva... |
| Feb 13, 2025 | Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quarter and full year ended December 31, 2024... |
| Jan 9, 2025 | RheumaGen, Inc. Launches with $15 Million Series A Financing to Advance a New Class of HLA Gene-Editing Therapies for Major Autoimmune Diseases | Company focused on editing the human leukocyte antigen (HLA) to transform autoimmunity
Lead program, RG0401, in development for treatment-resistant or refractory rheumatoid arthritis (RA), as a one-time, curative treatment
AURORA, CO, Janua... |
| Nov 19, 2024 | Verona Pharma Announces December 2024 Investor Conference Participation | LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in December 2024:
... |
| Nov 5, 2024 | Verona Pharma to Present at Jefferies London Healthcare Conference | LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the Jefferies London Healthcare Conference o... |
| Nov 4, 2024 | Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3
Through October more than 2,200 unique prescribers and more than 5,000 prescriptions filled across a broad COPD population
Pipeline exp... |
| Nov 4, 2024 | Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3
Through October more than 2,200 unique prescribers and more than 5,000 prescriptions filled across a broad COPD population
Pipeline exp... |
| Oct 21, 2024 | Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the third quarter ended September 30, 2024 on Monday, No... |
| Sep 30, 2024 | Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024 | Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 in a broad COPD population
LONDON and RALEIGH, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma... |
| Sep 30, 2024 | Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024 | LONDON and RALEIGH, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces four oral presentations and two posters on analyses from its successful Phase 3 ENHANCE studies with ... |
| Sep 5, 2024 | Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024 | One oral presentation and three posters support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4
LONDON and RALEIGH, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... |
| Sep 5, 2024 | Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024 | One oral presentation and three posters support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4
LONDON and RALEIGH, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... |
| Aug 8, 2024 | Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update | OhtuvayreTM (ensifentrine) now available; patient shipments started
Strong balance sheet supports commercialization and pipeline expansion
Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST
LONDON and RALEIGH, N.C., Aug. 08, 2024 (GLOBE... |
| Aug 8, 2024 | Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results | Initiated enrollment in Phase 2 clinical trial of XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC)
Initiated enrollment in Phase 1B monot... |
| Jul 30, 2024 | Verona Pharma to Present at 44th Annual Canaccord Growth Conference | LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the 44th Annual Canaccord Growth Conference ... |
| Jul 25, 2024 | Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the second quarter ended June 30, 2024 on Thursday, Augu... |
| Jul 25, 2024 | Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the second quarter ended June 30, 2024 on Thursday, Augu... |
| Jun 26, 2024 | Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine) | Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients
First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects
Conference call tomorrow at 8:30 a.m. ED... |
| Jun 13, 2024 | Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors | WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today annou... |
| May 7, 2024 | TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors | Accomplished industry veteran brings deep strategic and operational expertise
DENVER–(BUSINESS WIRE)–May 7, 2024– TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy ... |
| May 2, 2024 | Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024 | PDUFA Target Action Date of June 26, 2024
Eight posters including two oral presentations support potential of ensifentrine,
an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4
LONDON and RALEIGH, N.C., May 02, 202... |
| Apr 30, 2024 | TriSalus Life Sciences Secures up to $50 Million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives | DENVER–(BUSINESS WIRE)–Apr. 30, 2024– TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced the closing of a debt financing facility for up to $50 million with OrbiMed, a healthcare investment firm. The capital is expected to provide... |
| Mar 26, 2024 | Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa | MCO-010 achieved its primary and key secondary endpoints with statistical significance and no serious adverse events
Data from the Phase 2b RESTORE trial demonstrate clinically meaningful vision improvement in legally blind individuals with... |
| Mar 11, 2024 | TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results | DENVER–(BUSINESS WIRE)–Mar. 11, 2024– TriSalus Life Sciences® Inc. (Nasdaq: TLSI) announced today that the Company will host a conference call and webcast on April 1, 2024, at 9:00 a.m. ET to discuss financial results for the fourth quarter... |
| Mar 6, 2024 | OnCusp Therapeutics Announces First Patient Dosed in Phase 1 Trial of CUSP06 in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors | --CUSP06 is a CDH6-directed Antibody-Drug Conjugate (ADC) with a differentiated profile and potentially best-in-class activity--
NEW YORK, March 6, 2024 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company d... |
| Mar 6, 2024 | OnCusp Therapeutics Announces First Patient Dosed in Phase 1 Trial of CUSP06 in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors | --CUSP06 is a CDH6-directed Antibody-Drug Conjugate (ADC) with a differentiated profile and potentially best-in-class activity--
NEW YORK, March 6, 2024 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company d... |
| Feb 29, 2024 | TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors | Data published in Current Medical Research and Opinion provide a comparison of the TriNav Infusion System vs. standard drug delivery and show the ability of TriNav to successfully treat sicker, treatment refractory, and higher disease burde... |
| Feb 29, 2024 | Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | PDUFA Target Action Date for ensifentrine of June 26, 2024
Commercialization preparations advance
Strong balance sheet supports commercialization and Company's growth
Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT
LONDON and RALEIGH... |
| Feb 28, 2024 | Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference | WALTHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today annou... |
| Jan 31, 2024 | Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference | WALTHAM, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today annou... |
| Jan 8, 2024 | Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies | Dosing XTX301 at 45 ug/kg once every three weeks (dose level 3) in ongoing Phase 1 trial, nearly 100x the maximum tolerated dose of rhIL-12, with no dose-limiting toxicities observed to date
Initiated patient dosing in Phase 1/2 trial for X... |
| Dec 14, 2023 | TriSalus Life Sciences Announces CMS Reimbursement for the TriNav® Infusion System via Assignment of a New Technology Healthcare Common Procedure Coding System (HCPCS) Code | DENVER–(BUSINESS WIRE)–TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, is pleased to announ... |
| Nov 7, 2023 | TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call | Call Scheduled for Tuesday, November 14, 2023, at 9:00 a.m. ET |
| Nov 4, 2023 | Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications | New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment by enabling performance of the TLR9 agonist, SD-101, in metastatic uveal melanoma, consistent with an earlier presentation fro... |
| Nov 3, 2023 | TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting | New data from PERIO-03 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment by enabling performance of a TLR9 agonist in pancreatic tumors |
| Oct 25, 2023 | TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at SITC Annual Meeting | DENVER–(BUSINESS WIRE)–Oct. 25, 2023– TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today... |
| Jul 20, 2023 | Verona Pharma to Report Second Quarter 2023 Financial Results and Provide Corporate Update | /EIN News/ -- LONDON and RALEIGH, N.C., July 20, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it wil... |
| Jun 27, 2023 | Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD | /EIN News/ -- LONDON and RALEIGH, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces the submission of a New Drug Application (“NDA”) to the US Food and Drug Administration ... |
| Jun 22, 2023 | Tagworks Pharmaceuticals Announces $65 Million in Series A Financing to Advance Click-to-Release Therapeutics | Financing round led by Ysios Capital and Gilde Healthcare with participation from Novartis Venture Fund, New Enterprise Associates, and Lightstone Ventures
Unique Click-to-Release platform enables on-target activation of antibody-drug conju... |
| May 24, 2023 | Verona Pharma to Present at Jefferies Healthcare Conference | /EIN News/ -- LONDON and RALEIGH, N.C., May 24, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the Jefferies Healthcare Confe... |
| May 11, 2023 | Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress | The Company is poised to commence Phase 3 for RZ358 in the third quarter of calendar year 2023
/EIN News/ -- REDWOOD CITY, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company de... |
| May 9, 2023 | Nektar Therapeutics Reports First Quarter 2023 Financial Results | SAN FRANCISCO, May 9, 2023 /PRNewswire/ -- Nektar Therapeutics NKTR today reported financial results for the first quarter ended March 31, 2023.
Cash and investments in marketable securities at March 31, 2023, were $456.8 million as compare... |
| May 2, 2023 | Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023 | 12 Abstracts and one Symposium further support potential of ensifentrine,
a first-in-class, selective, dual inhibitor of PDE3 and PDE4
Conference call May 23 at 4:00 p.m. EDT / 9:00 p.m. BST
LONDON and RALEIGH, N.C., May 02, 2023 (GLOBE NEW... |
| Mar 28, 2023 | Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates | - Bicycle and Novartis will collaborate on the discovery and development of multiple targeted radioligand therapies in oncology |
| Mar 16, 2023 | Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01 | DisTinGuish Trial of DKN-01 plus tislelizumab and chemotherapy to continue as a clinical collaboration
CAMBRIDGE, Mass., March 16, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. LPTX, a biotechnology company focused on developing targeted and... |
| Feb 10, 2023 | Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress | /EIN News/ -- Initiated Phase 2 proof-of-concept study of RZ402
Anticipate initiation of global Phase 3 clinical study for RZ358 in mid 2023
REDWOOD CITY, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-s... |
| Jan 31, 2023 | uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1 | /EIN News/ -- ~ License of APB-102 further strengthens uniQure’s pipeline of innovative gene therapies to treat neurological disorders and miRNA-based gene silencing programs ~
~ APB-102 and uniQure’s c9orf72-ALS program have the potential ... |
| Dec 20, 2022 | Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD | Statistically significant improvements in lung function, symptoms and quality of life
36% reduction in rate of exacerbations over 24 weeks
Well tolerated safety profile over 48 weeks
NDA submission planned for 1H 2023
Conference call today ... |
| Dec 12, 2022 | CTI BioPharma Presents New Anemia Benefit Data from Pacritinib Program at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition | SEATTLE, Dec. 11, 2022 /PRNewswire/ -- CTI BioPharma Corp. CTIC today announced an oral presentation and two poster presentations from the Company's pacritinib program at the 64th American Society of Hematology (ASH®) Annual Meeting and Exp... |
| Nov 21, 2022 | Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference | CAMBRIDGE, Mass., Nov. 21, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. LPTX, a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Offic... |
| Nov 9, 2022 | Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update | /EIN News/ -- Access to up to $400 million expected to provide cash runway through at least 2025
Top-line Phase 3 ENHANCE-1 data expected around the end of 2022
Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT
LONDON and RALEIGH, N.C.... |
| Oct 26, 2022 | Verona Pharma to Report Third Quarter 2022 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its f... |
| Oct 20, 2022 | Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting | REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devast... |
| Oct 17, 2022 | Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance | LONDON and RALEIGH, N.C., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces it has entered into a debt financing facility (“debt facility”) providing the Company with access to ... |
| Oct 10, 2022 | Rigel Provides Update on Plans for sNDA for wAIHA Program Following FDA Feedback | --Announces Workforce Reduction--
SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. RIGL today announced that it has received guidance from the U.S. Food and Drug Administration (FDA)'s review of the Com... |
| Sep 15, 2022 | Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress | Announced a $130 million registered direct offering and concurrent private placement priced at-the-market
Late-breaking oral presentation from Phase 2b RIZE study of RZ358 presented at ESPE 2022
Phase 2 proof-of-concept study of RZ402 expec... |
| Sep 7, 2022 | Rezolute Announces Presentation at the 60th Annual ESPE Meeting | Data from Phase 2b RIZE Study in congenital hyperinsulinism will be presented in oral presentation
REDWOOD CITY, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated ... |
| Sep 5, 2022 | Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress | Median Progression-Free Survival of 11.3 months in first-line gastric cancer patients treated with DKN-01 plus tislelizumab and CAPOX, exceeding benchmarks in the overall population and in DKK1 and PD-L1 subgroups
Median Overall Survival is... |
| Aug 30, 2022 | Opthea Reports Fiscal Year 2022 Financial Results and Corporate Highlights | Secured up to US$170m in non-dilutive financing
Received commitments for well supported US$90m equity financing; closed first tranche for US$41.9 million
Expanded management team and US operations with appointment of C-Suite Executives
Elec... |
| Aug 29, 2022 | Verona Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference | LONDON and RALEIGH, N.C., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the H.C. Wainwright 24th Annual Global Inve... |
| Aug 24, 2022 | Verona Pharma strengthens commercialization leadership team | LONDON and RALEIGH, N.C., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, continues its preparation for comme... |
| Aug 22, 2022 | CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SEATTLE, Aug. 22, 2022 /PRNewswire/ -- CTI BioPharma Corp. CTIC today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards o... |
| Aug 19, 2022 | Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China | LONDON and RALEIGH, N.C., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc VRNA ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its development... |
| Aug 19, 2022 | Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China | LONDON and RALEIGH, N.C., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its development partner, ... |
| Aug 17, 2022 | Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML | Companion diagnostic would be used following potential regulatory approval of entospletinib to screen for NPM1 mutation present in approximately one-third of all patients with AML
Entospletinib is currently being studied in the Phase 3 AGIL... |
| Aug 16, 2022 | Halozyme Therapeutics, Inc. Announces Upsize and Pricing of Private Offering of $625 Million of Convertible Senior Notes due 2028 | SAN DIEGO, Aug. 15, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. HALO ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced the pricing of $625.0 million aggrega... |
| Aug 16, 2022 | Opthea Announces Presentation at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference | MELBOURNE, Australia, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that C... |
| Aug 15, 2022 | Verona Pharma plc Announces Closing of Upsized Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional ADSs | LONDON and RALEIGH, N.C., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announced today the closing of its ... |
| Aug 14, 2022 | Opthea Secures up to US$170 Million in Non-Dilutive Financing for OPT-302 in wet AMD | Carlyle and its life sciences franchise Abingworth, working with their recently formed development company Launch Therapeutics (Launch Tx), to provide non-dilutive financing of up to US$170M, consisting of a US$120M commitment and an option... |
| Aug 9, 2022 | Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD | Statistically significant improvements in key measures of lung function
42% reduction in rate of exacerbations over 24 weeks
Well tolerated with safety results similar to placebo
Conference call today at 8:30 a.m. EDT / 1:30 p.m. BST
LONDON... |
| Aug 9, 2022 | Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update | Ensifentrine met primary and secondary endpoints of evaluating lung function in Phase 3 ENHANCE-2 trial for COPD
Top-line Phase 3 ENHANCE-1 data expected around the end of 2022
Conference call today at 8:30 a.m. EDT / 1:30 p.m. BST
LONDON a... |
| Aug 8, 2022 | Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-2 Trial of Nebulized Ensifentrine for COPD | LONDON and RALEIGH, N.C., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will re... |
| Jul 29, 2022 | Verona Pharma to Report Second Quarter 2022 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., July 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results ... |
| Jul 25, 2022 | Lygos and Flexible Solutions International Announce Registration Statement on Form S-4 Related to Proposed Merger | BERKELEY, Calif. and VICTORIA, British Columbia, July 25, 2022 (GLOBE NEWSWIRE) -- Lygos, Inc., a vertically integrated biotechnology provider of sustainable specialty ingredients, and Flexible Solutions International Inc. (FSI) (NYSE Ameri... |
| Jun 9, 2022 | Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD | LONDON and RALEIGH, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces it has completed pa... |
| Jun 6, 2022 | Verona Pharma to Host KOL Event on June 16, 2022 | LONDON and RALEIGH, N.C., June 06, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), today announces it will host an in-person KOL event for analysts and investors on Thursday, June 16, 2022, at 8:00 AM ET, in New... |
| May 25, 2022 | Verona Pharma to Present at Jefferies Healthcare Conference | LONDON and RALEIGH, N.C., May 25, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces that Chris Martin, Senior Vice President of Commercial, will present a company overview at the Jefferies Healthcare Con... |
| May 24, 2022 | Travecta Therapeutics Announces In-Person Presentation at 2022 BIO International Convention | SINGAPORE and PRINCETON, N.J., May 24, 2022 /PRNewswire/ -- Travecta Therapeutics, Pte Ltd., a private biopharmaceutical company pioneering transformative treatments for serious neurological conditions by utilizing a natural transport syste... |
| May 12, 2022 | Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress | Announced a $130 million registered direct offering and concurrent private placement
Positive topline results from Phase 2b RIZE study of RZ358 exceeded expectations and demonstrated highly significant reduction in hypoglycemia events, ~75%... |
| May 11, 2022 | Opthea To Present at Upcoming Investor Conferences | MELBOURNE, Australia, May 11, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr Megan... |
| May 10, 2022 | Opthea Presentation at The Retina World Congress 2022 | MELBOURNE, Australia, May 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announces a prese... |
| May 9, 2022 | Verona Pharma to Present Successful TQT Analysis Demonstrating No Clinically Relevant Effect on Cardiac Conduction at the American Thoracic Society 2022 | LONDON and RALEIGH, N.C., May 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the presentation of an abstract demonstrati... |
| May 5, 2022 | Opthea Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) Presented at ARVO 2022 | MELBOURNE, Australia., May 05, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq: OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced... |
| May 4, 2022 | Rezolute to Host Corporate Update Call on May 4, 2022 | REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for ... |
| May 4, 2022 | Verona Pharma Announces May 2022 Investor Conference Participation | LONDON and RALEIGH, N.C., May 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces the company will participate in the following conferences in May 2022:
LifeSci Partners Virtual Immunology & Inflam... |
| May 4, 2022 | Rezolute, Inc. Announces Closing of Registered Direct Offering | REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for ... |
| May 3, 2022 | Verona Pharma Reports First Quarter 2022 Financial Results and Provides Corporate Update | Phase 3 ENHANCE-2 trial on target to report top-line COPD data in Q3 2022
James Brady joined the Board as Non-Executive Director
Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST
LONDON and RALEIGH, N.C., May 03, 2022 (GLOBE NEWSWIRE) ... |
| May 1, 2022 | Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market | REDWOOD CITY, Calif., May 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for ... |
| May 1, 2022 | Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism | Highly significant ~75% reduction in hypoglycemia events at anticipated therapeutic doses
≥50% improvement in hypoglycemia in 100% of patients in high-dose cohort, with no adverse drug reactions or clinically significant hyperglycemia
Study... |
| Apr 29, 2022 | Opthea Presenting Clinical Data at ARVO 2022 Annual Meeting | MELBOURNE, Australia, April 29, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announces the p... |
| Apr 26, 2022 | RZ358 Phase 2b (RIZE Study) Topline Data to be Unveiled at Pediatric Endocrine Society Annual Meeting on May 1, 2022 | Rezolute to host conference call presentation and discussion of the data on Sunday, May 1 at 2:30 p.m. ET
REDWOOD CITY, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company ded... |
